Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines

The skin represents an excellent site for vaccine inoculation due to its natural role as a first line of contact with foreign pathogens and the high local frequency of antigen presenting cells. To facilitate skin-directed immunization, a new technique has been developed (termed microporation) whereby a vaporization process is used to remove tiny areas of the stratum corneum creating microscopic pores that allow access to the underlying viable epidermis. Reporter gene expression was 100-fold increased following application of an adenovirus vector to microporated skin when compared to intact skin. Furthermore, 10–100-fold greater cellular and humoral immune responses were observed following topical administration of an adenovirus vaccine to microporated skin versus intact skin. Hairless mice responded to the microporated adenovirus vaccine equivalently to mice with normal hair follicle distribution demonstrating the activity of the microporated vaccine was not related to follicle count. In a tumor challenge model using a surrogate antigen, microporation increased vaccine efficacy by approximately 100-fold compared to intact skin. Finally, microporation enabled delivery of an adenovirus vaccine carrying a relevant melanoma antigen resulting in the development of auto-immune vitiligo and tumor protection. Thus, the microporation technology has proven to be a reliable and easy method to enable skin-directed vaccination.

[1]  T. Tüting,et al.  Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism , 2001, Gene Therapy.

[2]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[3]  Jonathan J. Lewis,et al.  Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.

[4]  D. Pardoll,et al.  Inducing autoimmune disease to treat cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Tang,et al.  Vaccination onto bare skin , 1997, Nature.

[6]  B. Spellberg The cutaneous citadel: a holistic view of skin and immunity. , 2000, Life sciences.

[7]  J. Kaplan,et al.  Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  B. W. Barry,et al.  Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  J. Gauldie,et al.  Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination , 1997, Gene Therapy.

[10]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  V. Schirrmacher,et al.  Superiority of the ear pinna over muscle tissue as site for DNA vaccination , 1998, Gene Therapy.

[12]  F. Graham,et al.  Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. , 1997, Human gene therapy.

[13]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[14]  A Smith,et al.  Fluorescein kinetics in interstitial fluid harvested from diabetic skin during fluorescein angiography: implications for glucose monitoring. , 1999, Diabetes technology & therapeutics.

[15]  E. Hirschowitz,et al.  Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma , 1998, Gene Therapy.

[16]  S. Rosenberg,et al.  Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.

[17]  M. Hitt,et al.  Human adenovirus vectors for gene transfer into mammalian cells. , 1997, Advances in pharmacology.

[18]  J. Gauldie,et al.  Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. , 2000, Cancer research.

[19]  A. Enk,et al.  Genetic immunization of mice with human tyrosinase‐related protein 2: Implications for the immunotherapy of melanoma , 2000, International journal of cancer.

[20]  F. Graham,et al.  Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. , 1996, Human gene therapy.

[21]  P. Khavari,et al.  Immunization via hair follicles by topical application of naked DNA to normal skin , 1999, Nature Biotechnology.

[22]  Y. Girerd-Chambaz,et al.  Intradermal DNA immunization by using jet-injectors in mice and monkeys. , 1999, Vaccine.

[23]  J. Bramson,et al.  The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen , 2002, Expert opinion on biological therapy.

[24]  C. Elmets,et al.  Protection against Tetanus by Needle-Free Inoculation of Adenovirus-Vectored Nasal and Epicutaneous Vaccines , 2001, Journal of Virology.

[25]  P. Upadhyay,et al.  Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. , 1999, Vaccine.

[26]  Ajay K. Banga,et al.  Electrically Assisted Transdermal And Topical Drug Delivery , 1998 .

[27]  F. Graham,et al.  An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. , 2000, Human gene therapy.

[28]  M. Allen,et al.  Microfabricated microneedles for gene and drug delivery. , 2000, Annual review of biomedical engineering.

[29]  S. Rosenberg,et al.  Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. , 1996, Journal of immunology.

[30]  C. Alving,et al.  Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.

[31]  Dexiang Chen,et al.  Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses , 2001, Journal of Virology.